Strengthening the Business Base through Solution-Based Sales and Healthcare Management Consulting
First written in FY2018. 15 of 26 entries say "Advanced", first in FY2019. Latest entry: 2026-09-30.
0 other companies' latest entry also says "Other".
- 2026-09-30OtherEarnings
「医療機器販売業の売上高は150億68百万円（前年同四半期比0.1％減）、セグメント利益は２億12百万円（前年同四半期比40.5％減）となりました。」
中核の医療機器販売業は売上高がほぼ横ばいとなった一方、セグメント利益が減少した。 - FY2026RestatedAnnual report
「In addition to selling equipment that helps medical institutions address management challenges, we expect higher sales from stronger solution-based sales combining system proposals and maintenance services, through improved customer satisfaction and profitability.」
The policy of strengthening solution-based sales combining equipment sales with system proposals and maintenance services was reaffirmed as a means of improving customer satisfaction and profitability. - FY2025-H1AdvancedAnnual report
「As a result, sales in the medical equipment sales business were ¥31,355 million, up 8.7% year on year, and segment profit was ¥1,125 million, up 1.9%.」
In the medical equipment sales business, sales were ¥31,355 million, up 8.7% year on year, and segment profit was ¥1,125 million, up 1.9%, updating the results of the core business, including expanded sales and consultative sales. - FY2024-Q3AdvancedAnnual report
「As a result, sales in the medical equipment sales business were ¥45,365 million, up 9.0% year on year, and segment profit was ¥1,671 million, up 6.1%.」
The medical equipment sales business recorded 9.0% year-on-year sales growth and 6.1% profit growth, with sales of ¥45,365 million and segment profit of ¥1,671 million. - FY2024-Q1AdvancedAnnual report
「Under these circumstances, although sales activities remained subject to certain constraints due to the COVID-19 pandemic, the 7 operating companies in our group each conducted sales activities.」
The operating structure was expanded from the previous 6-company structure to a 7-company structure, with each operating company continuing its own sales activities. - FY2023RestatedAnnual report
「Although the fiscal year ended May 2023 remained challenging, with intermittent waves of COVID-19 infections, we pursued various initiatives to strengthen Group-wide profitability and expand our customer base, in addition to actively proposing products in core categories and appropriately responding to medical institutions' capital investment demand supported by subsidies for COVID-19 countermeasures.」
Sales initiatives combining active proposals in core product categories, responses to capital investment demand, stronger profitability and customer-base expansion continued. - FY2023-Q3AdvancedAnnual report
「As a result, sales in the medical equipment sales business were ¥41,613 million, up 2.8% year on year, and segment profit was ¥1,574 million, up 4.5%.」
The medical equipment sales business recorded 2.8% year-on-year sales growth and 4.5% profit growth, with segment profit turning higher after sales growth and profit decline in the previous quarter. - FY2023-Q2Revenue growth and decline in segment profitAnnual report
「As a result, sales in the medical equipment sales business were ¥27,596 million, up 1.3% year on year, and segment profit was ¥1,041 million, down 3.0%.」
Sales in the medical equipment sales business increased year on year, while segment profit declined 3.0%. - FY2023-Q1AdvancedAnnual report
「Against this backdrop, although the COVID-19 pandemic placed certain restrictions on sales activities, each of the Group's 6 operating companies conducted its respective sales activities within the permitted scope.」
The 6 operating companies continued their respective sales activities, and sales in the medical equipment sales business were ¥13,446 million, with segment profit of ¥487 million. - FY2022-Q3AdvancedAnnual report
「Under these conditions, each of the Group's 5 operating companies conducted its own sales activities during the COVID-19 pandemic. In the medical equipment sales business, the Group's core business, the core product categories, including advanced medical equipment such as diagnostic imaging equipment and operating-room equipment for acute-care medical institutions, and minimally invasive treatment equipment such as endoscopy-related products, recorded year-on-year growth. In addition, demand from medical institutions for COVID-19-related products, including various testing devices, continued, resulting in strong sales performance across the Group. As a result, sales in the medical equipment sales business were ¥40,479 million, and segment profit was ¥1,506 million, up 28.5% year on year.」
Sales activities by each of the 5 operating companies, responses in the core product categories, and the capture of demand for COVID-19-related products resulted in a 28.5% year-on-year increase in segment profit in the medical equipment sales business. - FY2022-Q2AdvancedAnnual report
「Accordingly, in the medical equipment sales business, the Group's core business, the core product categories, including advanced medical equipment such as diagnostic imaging equipment and operating-room equipment for acute-care medical institutions, and minimally invasive treatment equipment such as endoscopy-related products, recorded year-on-year growth. In addition, demand from medical institutions for COVID-19-related products, including infection-control equipment and various testing devices, contributed to strong sales performance across the Group. As a result, sales in the medical equipment sales business were ¥27,243 million, and segment profit was ¥1,073 million, up 39.7% year on year.」
In addition to year-on-year growth in the core product categories, demand for infection-control equipment and testing devices was captured, and segment profit in the medical equipment sales business increased 39.7% year on year to ¥1,073 million. - FY2022-Q1AdvancedAnnual report
「Accordingly, in the medical equipment sales business, the Group's core business, the core product categories, including advanced medical equipment such as diagnostic imaging equipment and operating-room equipment for acute-care medical institutions, and minimally invasive treatment equipment such as endoscopy-related products, recorded year-on-year growth. In addition, demand from medical institutions for COVID-19-related products, including infection-control equipment and various testing devices, contributed to strong sales performance across the Group. As a result, sales in the medical equipment sales business were ¥12,835 million, and segment profit was ¥404 million, up 61.4% year on year.」
The core product categories recorded year-on-year growth, while demand for infection-control equipment and testing devices also contributed. Sales in the medical equipment sales business were ¥12,835 million and segment profit was ¥404 million, up 61.4% year on year. - FY2021AdvancedAnnual report
「In core product categories, including advanced medical equipment such as diagnostic imaging equipment and operating-room equipment for acute-care medical institutions, and minimally invasive treatment equipment such as endoscopy-related products, we introduced remote sales and strengthened sales activities by establishing a multifaceted sales organization. We also actively pursued proposals to meet medical institutions' demand for COVID-19-related products, including infection-control equipment such as air-disinfection equipment and various testing devices.」
As part of the response to the COVID-19 pandemic, remote sales and a multifaceted sales organization were introduced, and proposals for infection-control equipment, testing devices and other products were developed. - FY2021-Q3AdvancedAnnual report
「As a result, sales in the medical equipment sales business were ¥49,464 million, up 3.8% year on year, and segment profit was ¥1,172 million, up 27.2%.」
As sales activities and consultative sales were strengthened, cumulative sales for the first 3 quarters in the medical equipment sales business increased 3.8% year on year and segment profit increased 27.2%. - FY2021-Q1RestatedAnnual report
「Under these conditions, each of the Group's 4 operating companies conducted sales activities within the permitted scope, while the Group promoted collaboration among its companies and worked to strengthen its competitiveness in the market, including by enhancing its ability to develop and propose plans covering the full scope of medical-practice management.」
Initiatives to strengthen market competitiveness through the sales activities of the 4 operating companies, collaboration across the Group, and planning and proposal capabilities covering the full scope of medical-practice management continued despite sales restrictions during the COVID-19 pandemic. - FY2020RestatedAnnual report
「Going forward, we will seek to expand the business by leveraging the respective strengths of the Group companies, promote collaboration among them, enhance our ability to develop and propose plans covering the full scope of medical-practice management, and strengthen our competitiveness in the market, with the aim of improving profitability.」
Under a 4-company structure, initiatives to improve profitability through mutual collaboration, planning and proposal capabilities in medical-practice management, and market competitiveness were reaffirmed. - FY2020-Q3AdvancedAnnual report
「In December 2019, we established a company specialising in highly specialised consulting services for medical management to address growing demand for management support for medical institutions, hospital-bed conversions, M&A and business succession, while enhancing synergies across the Group. We also launched a structure comprising 4 Group operating companies.」
A company specializing in medical-practice management consulting was established in December 2019, giving concrete form to support for medical institution management, hospital-bed conversion, M&A and business succession. - FY2020-Q2AdvancedAnnual report
「Under these conditions, the Group strengthened its sales organization through its 3 operating companies and sought to enhance its competitiveness in regional markets by actively pursuing consultative sales to medical institutions, its customers, including proposals to improve the efficiency of medical-supplies management and reduce costs. In particular, to strengthen the medical equipment sales business, its core business, the Group actively expanded sales in core product categories such as advanced medical equipment and minimally invasive treatment equipment, while continuing to promote its SPD (Supply Processing and Distribution) business.」
As the Group strengthened its sales organization, pursued consultative sales, expanded sales in core product categories and promoted its SPD business, sales in the medical equipment sales business increased 12.7% year on year and segment profit increased 107.5%. - FY2020-Q1AdvancedAnnual report
「As a result, sales in the medical equipment sales business were ¥15,884 million, up 11.9% year on year, and segment profit was ¥257 million, up 137.4%.」
As sales activities were strengthened and expanded in the core product categories, sales in the medical equipment sales business increased 11.9% year on year and segment profit increased 137.4%. - FY2019AdvancedAnnual report
「In the medical equipment sales business, our core business, we recorded higher sales than in the previous year across all business areas, as initiatives to increase value added through a stronger sales organization and enhance competitiveness in regional markets took effect, while market conditions also improved, including a recovery in medical institutions' demand for capital investment.」
The full-year results showed sales above the previous year's level across all business areas of the medical equipment sales business, supported by initiatives to strengthen the sales organization and increase value added. - FY2019-Q3RestatedAnnual report
「In the medical equipment sales business, our core business, we have pursued customer-focused sales activities, including actively making proposals to medical institutions, our customers, to improve the efficiency of medical-supplies management and reduce costs, thereby seeking to strengthen our competitiveness in regional markets.」
The policy of strengthening competitiveness in regional markets through customer-focused sales activities proposing more efficient medical-supplies management and cost reduction has been reaffirmed. - FY2019-Q2RestatedAnnual report
「In the medical equipment sales business, the Group's core business, we are seeking to strengthen our competitiveness in regional markets by actively pursuing consultative sales to medical institutions, our customers, including proposals to improve the efficiency of medical-supplies management and reduce costs.」
Initiatives to strengthen competitiveness in regional markets through consultative sales, including more efficient medical-supplies management and cost reduction, have been reaffirmed. - FY2019-Q1RestatedAnnual report
「In addition, 山下医科器械株式会社, the Group's core operating company, is working to increase customer value and strengthen its competitiveness in regional markets by reinforcing its sales organization.」
Initiatives to increase customer value and regional competitiveness by strengthening the sales organization at the core operating company are continuing. - FY2018First statedAnnual report
「To address increasingly sophisticated customer needs and a more challenging operating environment, the Company will strengthen its ability to develop and propose plans for customers of Group companies, promote coordination among Group companies, and further enhance its consulting capabilities across healthcare management. In addition to supporting the opening of new clinics and the construction and relocation of hospitals, the Company will seek to improve customer satisfaction through solution-based sales activities.」
Strengthening the customer base by combining proposal capabilities, collaboration across the Group, medical practice management consulting, and support for opening and relocating facilities is presented as a standalone priority.